NMD Pharma at ICFSR 2022 - Symposium 4 - Part 4 - Q&A

Events
Written By Stine Krag Brunvold

Neuromuscular Junction Transmission Failure in Sarcopenia

See the ICFSR program here:

Stine Krag Brunvold
Previous

NMD Pharma at ICFSR 2022 - Symposium 4 - Part 3
Next

Spinal Muscular Atrophy (SMA) Patient Perspective: Our Clinical Trial Manager Thomas Grønnebæk caught up with Eden